Lin Christine, Khetani Salman R
School of Biomedical Engineering, Colorado State University, Fort Collins, Colorado.
Department of Bioengineering, University of Illinois at Chicago, Chicago, Illinois.
Curr Protoc Toxicol. 2017 May 2;72:14.17.1-14.17.23. doi: 10.1002/cptx.23.
Drug clearance rates from the body can determine drug exposure that can affect efficacy or toxicity. Thus, accurate prediction of drug clearance during preclinical development can help guide dose selection in humans, but animal testing is not always predictive of human outcomes. Because hepatic drug metabolism is a rate-limiting step in the overall clearance of many drugs, primary human hepatocytes (PHHs) in suspension cultures or monolayers are used for drug clearance predictions. Yet, the precipitous decline in drug metabolism capacity can lead to significant underestimation of clearance rates, particularly for low turnover compounds that have desirable one-pill-a-day dosing regimens. In contrast, micropatterned co-cultures (MPCCs) of PHHs and fibroblasts display phenotypic stability for several weeks and can help mitigate the limitations of conventional cultures. Here, we describe protocols to create and use MPCCs for drug clearance predictions, and for modeling clinically-relevant drug-drug interactions that can affect drug clearance. © 2017 by John Wiley & Sons, Inc.
药物从体内的清除率可决定药物暴露量,而药物暴露量会影响疗效或毒性。因此,在临床前开发过程中准确预测药物清除率有助于指导人体剂量选择,但动物试验并不总是能够预测人体结果。由于肝脏药物代谢是许多药物整体清除过程中的限速步骤,悬浮培养或单层培养的原代人肝细胞(PHH)被用于药物清除率预测。然而,药物代谢能力的急剧下降可能导致清除率被显著低估,尤其是对于那些具有理想的每日一片给药方案的低周转率化合物。相比之下,PHH与成纤维细胞的微图案共培养物(MPCC)在数周内表现出表型稳定性,有助于缓解传统培养方法的局限性。在此我们描述创建并使用MPCC进行药物清除率预测以及对可能影响药物清除率的临床相关药物相互作用进行建模的方案。© 2017约翰威立国际出版公司